The progress and prospects of targeting the adenosine pathway in cancer immunotherapy DOI Creative Commons
Yuying Yang, Lin Zhu, Yantao Xu

и другие.

Biomarker Research, Год журнала: 2025, Номер 13(1)

Опубликована: Май 19, 2025

Abstract Despite the notable success of cancer immunotherapy, its effectiveness is often limited in a significant proportion patients, highlighting need to explore alternative tumor immune evasion mechanisms. Adenosine, key metabolite accumulating hypoxic regions, has emerged as promising target oncology. Inhibiting adenosinergic pathway not only inhibits progression but also holds potential enhance immunotherapy outcomes. Multiple therapeutic strategies targeting this are being explored, ranging from preclinical studies clinical trials. This review examines complex interactions between adenosine, receptors, and microenvironment, proposing axis boost anti-tumor immunity. It evaluates early data on pharmacological inhibitors discusses future directions for improving responses.

Язык: Английский

Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies DOI Open Access
Haolong Lin,

Xiuxiu Yang,

Shanwei Ye

и другие.

Biomedicine & Pharmacotherapy, Год журнала: 2024, Номер 178, С. 117252 - 117252

Опубликована: Авг. 3, 2024

Chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating hematological malignancies and certain solid tumors. However, its efficacy is often hindered by negative relapses resulting from escape. This review firstly elucidates the mechanisms underlying escape during CAR-T therapy, including enrichment of pre-existing target-negative tumor clones, gene mutations or alternative splicing, deficits processing, redistribution, lineage switch, epitope masking, trogocytosis-mediated loss. Furthermore, we summarize various strategies to overcome escape, evaluate their advantages limitations, propose future research directions. Thus, aim provide valuable insights enhance effectiveness therapy.

Язык: Английский

Процитировано

13

CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors DOI Creative Commons

Yonggui Tian,

Liubo Zhang,

Yu P

и другие.

Cancer Immunology Immunotherapy, Год журнала: 2025, Номер 74(2)

Опубликована: Янв. 3, 2025

Язык: Английский

Процитировано

2

Photoimmunotherapy for cancer treatment based on organic small molecules: Recent strategies and future directions DOI Creative Commons
Deming Zhao, Xin Wen, Jiani Wu

и другие.

Translational Oncology, Год журнала: 2024, Номер 49, С. 102086 - 102086

Опубликована: Авг. 24, 2024

Photodynamic therapy (PDT) is considered as a promising anticancer approach, owning to its high efficiency and spatiotemporal selectivity. Ample evidence indicated that PDT can trigger immunogenic cell death by releasing antigens activate immune cells promote anti-tumor immunity. Nevertheless, the inherent nature of tumors their complex heterogeneity often limits PDT, which be overcome with novel strategy photo-immunotherapy (PIT) strategy. By exploring principles induction ICD enhancement, combined other therapies such chemotherapy or checkpoint blockade, tailored solutions designed address specific challenges drug resistance, hypoxic conditions, tumor immunosuppressive microenvironments (TIMEs), enables targeted enhancement systemic immunity most distant recurrent cancers. The present article summarizes strategies PIT discusses recent existing limitations. More importantly, we anticipate perspectives presented herein will help clinical translation associated PIT.

Язык: Английский

Процитировано

3

Natural killer cell-based cancer immunotherapy: from basics to clinical trials DOI Creative Commons
Ying‐Hong Shi,

Donglin Hao,

Hui Qian

и другие.

Experimental Hematology and Oncology, Год журнала: 2024, Номер 13(1)

Опубликована: Окт. 16, 2024

Cellular immunotherapy exploits the capacity of human immune system in self-protection and surveillance to achieve anti-tumor effects. Natural killer (NK) cells are lymphocytes innate they display a unique inherent ability identify eliminate tumor cells. In this review, we first introduce basic characteristics NK physiological pathological milieus, followed by discussion their effector function immunosuppression microenvironment. Clinical strategies reports regarding cellular therapy analyzed context treatment, especially against solid tumors. Given widely studied T-cell recent years, particularly chimeric antigen receptor (CAR) therapy, compare technical features NK- based therapies at clinical front. Finally, challenges potential solutions for both T cell-based immunotherapies treating malignancies delineated. By overviewing its applications, envision NK-cell as an up-and-comer cancer therapeutics.

Язык: Английский

Процитировано

3

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy DOI Creative Commons
Weiyue Zhang, Xin Huang

Journal of Hematology & Oncology, Год журнала: 2024, Номер 17(1)

Опубликована: Ноя. 13, 2024

Chimeric antigen receptor (CAR) cell therapy has achieved groundbreaking success in treating hematological malignancies. However, its application to solid tumors remains challenging due complex manufacturing processes, limited vivo persistence, and transient therapeutic effects. In CAR-immune cells induced by gene delivery systems loaded with CAR genes gene-editing tools have shown efficiency for anti-tumor immunotherapy. situ programming of autologous immune avoids the safety concerns allogeneic cells, manufacture could be standardized. Therefore, editing generation might potentially overcome abovementioned limitations current therapy. This review mainly focuses on structures, tools, techniques applied immunotherapy help design develop The recent applications both hematologic malignancies are investigated. To sum up, holds promise offering a practical, cost-effective, efficient, safe, widely applicable approach next-generation

Язык: Английский

Процитировано

3

SPRY1 regulates macrophage M1 polarization in skin aging and melanoma prognosis DOI

Rongxin Zhao,

Xun Zhang,

Yingnan Geng

и другие.

Translational Oncology, Год журнала: 2025, Номер 54, С. 102331 - 102331

Опубликована: Фев. 28, 2025

Язык: Английский

Процитировано

0

Liver Metastasis in Cancer: Molecular Mechanisms and Management DOI Creative Commons
Wenchao Xu,

Jia Xu,

Jianzhou Liu

и другие.

MedComm, Год журнала: 2025, Номер 6(3)

Опубликована: Фев. 27, 2025

Abstract Liver metastasis is a leading cause of mortality from malignant tumors and significantly impairs the efficacy therapeutic interventions. In recent years, both preclinical clinical research have made significant progress in understanding molecular mechanisms strategies liver metastasis. Metastatic tumor cells different primary sites undergo highly similar biological processes, ultimately achieving ectopic colonization growth liver. this review, we begin by introducing inherent metastatic‐friendly features We then explore panorama conclude three continuous, yet distinct phases based on liver's response to This includes metastatic sensing stage, stress support stage. discuss intricate interactions between various resident recruited cells. addition, emphasize critical role spatial remodeling immune Finally, review advancements challenges faced management Future precise antimetastatic treatments should fully consider individual heterogeneity implement targeted interventions stages

Язык: Английский

Процитировано

0

Fibroblast activation protein-targeted chimeric antigen-receptor-modified NK cells alleviate cardiac fibrosis DOI Creative Commons
Qi Zheng, Hao Li, Yongliang Jiang

и другие.

International Immunopharmacology, Год журнала: 2025, Номер 157, С. 114760 - 114760

Опубликована: Май 3, 2025

Язык: Английский

Процитировано

0

The progress and prospects of targeting the adenosine pathway in cancer immunotherapy DOI Creative Commons
Yuying Yang, Lin Zhu, Yantao Xu

и другие.

Biomarker Research, Год журнала: 2025, Номер 13(1)

Опубликована: Май 19, 2025

Abstract Despite the notable success of cancer immunotherapy, its effectiveness is often limited in a significant proportion patients, highlighting need to explore alternative tumor immune evasion mechanisms. Adenosine, key metabolite accumulating hypoxic regions, has emerged as promising target oncology. Inhibiting adenosinergic pathway not only inhibits progression but also holds potential enhance immunotherapy outcomes. Multiple therapeutic strategies targeting this are being explored, ranging from preclinical studies clinical trials. This review examines complex interactions between adenosine, receptors, and microenvironment, proposing axis boost anti-tumor immunity. It evaluates early data on pharmacological inhibitors discusses future directions for improving responses.

Язык: Английский

Процитировано

0